News | ANAVEX

View all Alzheimer's Disease Anavex2-73 Events News Releases PDD PIPELINE Press Rett Syndrome

Anavex Announces Two-Year Clinical Extension Study of ANAVEX 2-73 and Presents Phase 2a Dose-Response Analysis at AAT Conference

Assessment of ANAVEX 2-73 in a MECP2 Rett Syndrome Mouse Model.

February 26, 2016

Anavex Presents Preclinical Results of ANAVEX 2-73 in Rett Syndrome

February 25, 2016

ANAVEX 2-73 Preclinical Data in New Indication to be Presented at ACTRIMS 2016

February 17, 2016

Sigma-1 Receptor Agonists Inhibit Oligodendrocyte Cytotoxicity Induced by Molecules Involved in Cell Damage in Multiple Sclerosis.

February 11, 2016

Anavex Reports Fiscal First Quarter 2016 Financial Results

February 8, 2016

Anavex to Present at 18th Annual BIO CEO & Investor Conference on February 9th 2016

February 2, 2016

14th International Athens / Springfield Symposium on Advances in Alzheimer Therapy

February 1, 2016

2016 Epilepsy Pipeline Conference

January 15, 2016

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2016

January 14, 2016

18th Annual BIO CEO & Investor Conference

January 12, 2016

Anavex Announces Positive Dose-Response Data for ANAVEX 2-73 in Alzheimer’s Disease Patients

January 11, 2016